Promis Neurosciences (PMN) Projected to Release Quarterly Earnings on Thursday

Promis Neurosciences (NASDAQ:PMN) is anticipated to post its Q2 2026 results before the market opens on Thursday, August 13th. Analysts expect Promis Neurosciences to post earnings of ($1.3786) per share for the quarter. Interested persons may visit the the company’s upcoming Q2 2026 earning overview page for the latest details on the call scheduled for Thursday, August 13, 2026 at 4:30 PM ET.

Promis Neurosciences (NASDAQ:PMN) last announced its quarterly earnings results on Tuesday, May 12th. The company reported ($1.26) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($1.06) by ($0.20). On average, analysts expect Promis Neurosciences to post $-5 EPS for the current fiscal year and $-4 EPS for the next fiscal year.

Promis Neurosciences Stock Up 0.1%

Shares of NASDAQ:PMN opened at $14.72 on Tuesday. The business’s 50 day moving average is $12.35 and its 200 day moving average is $13.48. The stock has a market cap of $132.04 million, a P/E ratio of -1.01 and a beta of -0.23. Promis Neurosciences has a 52-week low of $6.27 and a 52-week high of $27.40.

Wall Street Analyst Weigh In

Several equities research analysts have weighed in on the company. Roth Capital assumed coverage on Promis Neurosciences in a report on Tuesday, July 7th. They issued a “buy” rating and a $19.00 target price for the company. Brookline Capital Markets upgraded Promis Neurosciences to a “strong-buy” rating in a research note on Wednesday, May 20th. Weiss Ratings lowered Promis Neurosciences from a “sell (d-)” rating to a “sell (e+)” rating in a research note on Thursday, June 11th. Zacks Research upgraded Promis Neurosciences to a “hold” rating in a report on Tuesday, June 9th. Finally, Chardan Capital set a $20.00 price objective on shares of Promis Neurosciences and gave the stock a “buy” rating in a research note on Monday, July 27th. Two research analysts have rated the stock with a Strong Buy rating, four have given a Buy rating, one has issued a Hold rating and one has assigned a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of “Moderate Buy” and a consensus price target of $31.50.

Institutional Trading of Promis Neurosciences

A hedge fund recently raised its position in Promis Neurosciences stock. Armistice Capital LLC grew its stake in Promis Neurosciences (NASDAQ:PMN) by 39.1% during the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The firm owned 2,974,518 shares of the company’s stock after acquiring an additional 836,622 shares during the quarter. Armistice Capital LLC owned about 5.53% of Promis Neurosciences worth $1,264,000 at the end of the most recent quarter. 50.13% of the stock is owned by institutional investors and hedge funds.

About Promis Neurosciences

Promis Neurosciences, Inc is a clinical‐stage biopharmaceutical company focused on the discovery and development of novel therapeutics for central nervous system disorders. The company’s research programs target cognitive impairment and other neurological symptoms associated with diseases such as Alzheimer’s disease and multiple sclerosis.

Leveraging a proprietary small‐molecule discovery platform, Promis Neurosciences advances both preclinical and early clinical candidates designed to modulate neural pathways involved in memory, learning and neuroinflammation.